Patient Derived Xenograft Models Professional Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Mice Model, Rats Model); Tumor Type (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, Other Tumor Model); End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Others)

Report Code: TIPRE00021843 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Xenograft animal models are primarily used for screenings and drug development for a wide range of diseases. Growing demand for personalized medicine is driving the growth of the patient-derived xenograft models market.

MARKET DYNAMICS

The patient derived xenograft models professional market is driving due to growing demand for personalized medicine, and rising R&D activities in the pharmaceutical industry. However, high cost of personalized PDX models is expected to hamper the growth of the global patient derived xenograft models professional market. Moreover, continuous support for cancer research from public as well as private sector is anticipated to drive demand the growth of the market.

MARKET SCOPE

The "Patient Derived Xenograft Models Professional Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of patient derived xenograft models professional market with detailed market segmentation by type, tumor type, and end user. The patient derived xenograft models professional market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Patient Derived Xenograft Models Professional market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The patient derived xenograft models professional market is segmented based on type, tumor type, and end user. Based on type, the market is segmented into mice model, rats model. Based on tumor type, the market is segmented into gastrointestinal tumor model, gynecological tumor model, respiratory tumor model, and other tumor model. Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutions, others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Patient Derived Xenograft Models Professional market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Patient Derived Xenograft Models Professional market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Patient Derived Xenograft Models Professional market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social, and technological factors effecting the Patient Derived Xenograft Models Professional market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Patient Derived Xenograft Models Professional market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Patient Derived Xenograft Models Professional market are anticipated to have lucrative growth opportunities in the future with the rising demand for Patient Derived Xenograft Models Professional market in the global market. Below mentioned is the list of few companies engaged in the Patient Derived Xenograft Models Professional market.

The report also includes the profiles of key players in Patient Derived Xenograft Models Professional market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Champions Oncology, Inc.
  •   Charles River Laboratories, Inc.
  •   Crown Bioscience, Inc.
  •   EPO Berlin-Buch GmbH
  •   Hera BioLabs
  •   Horizon Discovery Group plc
  •   Oncodesign
  •   Pharmatest Services Ltd
  •   Urolead
  •   Xentech

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Patient Derived Xenograft Models Professional Market - By Type
1.3.2 Patient Derived Xenograft Models Professional Market - By Tumor Type
1.3.3 Patient Derived Xenograft Models Professional Market - By End User
1.3.4 Patient Derived Xenograft Models Professional Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET - GLOBAL MARKET ANALYSIS
6.1. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL - GLOBAL MARKET OVERVIEW
6.2. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. MICE MODEL
7.3.1. Overview
7.3.2. Mice Model Market Forecast and Analysis
7.4. RATS MODEL
7.4.1. Overview
7.4.2. Rats Model Market Forecast and Analysis
8. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET - REVENUE AND FORECASTS TO 2028 - TUMOR TYPE
8.1. OVERVIEW
8.2. TUMOR TYPE MARKET FORECASTS AND ANALYSIS
8.3. GASTROINTESTINAL TUMOR MODEL
8.3.1. Overview
8.3.2. Gastrointestinal Tumor Model Market Forecast and Analysis
8.4. GYNECOLOGICAL TUMOR MODEL
8.4.1. Overview
8.4.2. Gynecological Tumor Model Market Forecast and Analysis
8.5. RESPIRATORY TUMOR MODEL
8.5.1. Overview
8.5.2. Respiratory Tumor Model Market Forecast and Analysis
8.6. OTHER TUMOR MODEL
8.6.1. Overview
8.6.2. Other Tumor Model Market Forecast and Analysis
9. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3.1. Overview
9.3.2. Pharmaceutical and Biotechnology Companies Market Forecast and Analysis
9.4. ACADEMIC AND RESEARCH INSTITUTIONS
9.4.1. Overview
9.4.2. Academic and Research Institutions Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Patient Derived Xenograft Models Professional Market Overview
10.1.2 North America Patient Derived Xenograft Models Professional Market Forecasts and Analysis
10.1.3 North America Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Type
10.1.4 North America Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Tumor Type
10.1.5 North America Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By End User
10.1.6 North America Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Countries
10.1.6.1 United States Patient Derived Xenograft Models Professional Market
10.1.6.1.1 United States Patient Derived Xenograft Models Professional Market by Type
10.1.6.1.2 United States Patient Derived Xenograft Models Professional Market by Tumor Type
10.1.6.1.3 United States Patient Derived Xenograft Models Professional Market by End User
10.1.6.2 Canada Patient Derived Xenograft Models Professional Market
10.1.6.2.1 Canada Patient Derived Xenograft Models Professional Market by Type
10.1.6.2.2 Canada Patient Derived Xenograft Models Professional Market by Tumor Type
10.1.6.2.3 Canada Patient Derived Xenograft Models Professional Market by End User
10.1.6.3 Mexico Patient Derived Xenograft Models Professional Market
10.1.6.3.1 Mexico Patient Derived Xenograft Models Professional Market by Type
10.1.6.3.2 Mexico Patient Derived Xenograft Models Professional Market by Tumor Type
10.1.6.3.3 Mexico Patient Derived Xenograft Models Professional Market by End User
10.2. EUROPE
10.2.1 Europe Patient Derived Xenograft Models Professional Market Overview
10.2.2 Europe Patient Derived Xenograft Models Professional Market Forecasts and Analysis
10.2.3 Europe Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Type
10.2.4 Europe Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Tumor Type
10.2.5 Europe Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By End User
10.2.6 Europe Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Patient Derived Xenograft Models Professional Market
10.2.6.1.1 Germany Patient Derived Xenograft Models Professional Market by Type
10.2.6.1.2 Germany Patient Derived Xenograft Models Professional Market by Tumor Type
10.2.6.1.3 Germany Patient Derived Xenograft Models Professional Market by End User
10.2.6.2 France Patient Derived Xenograft Models Professional Market
10.2.6.2.1 France Patient Derived Xenograft Models Professional Market by Type
10.2.6.2.2 France Patient Derived Xenograft Models Professional Market by Tumor Type
10.2.6.2.3 France Patient Derived Xenograft Models Professional Market by End User
10.2.6.3 Italy Patient Derived Xenograft Models Professional Market
10.2.6.3.1 Italy Patient Derived Xenograft Models Professional Market by Type
10.2.6.3.2 Italy Patient Derived Xenograft Models Professional Market by Tumor Type
10.2.6.3.3 Italy Patient Derived Xenograft Models Professional Market by End User
10.2.6.4 Spain Patient Derived Xenograft Models Professional Market
10.2.6.4.1 Spain Patient Derived Xenograft Models Professional Market by Type
10.2.6.4.2 Spain Patient Derived Xenograft Models Professional Market by Tumor Type
10.2.6.4.3 Spain Patient Derived Xenograft Models Professional Market by End User
10.2.6.5 United Kingdom Patient Derived Xenograft Models Professional Market
10.2.6.5.1 United Kingdom Patient Derived Xenograft Models Professional Market by Type
10.2.6.5.2 United Kingdom Patient Derived Xenograft Models Professional Market by Tumor Type
10.2.6.5.3 United Kingdom Patient Derived Xenograft Models Professional Market by End User
10.2.6.6 Rest of Europe Patient Derived Xenograft Models Professional Market
10.2.6.6.1 Rest of Europe Patient Derived Xenograft Models Professional Market by Type
10.2.6.6.2 Rest of Europe Patient Derived Xenograft Models Professional Market by Tumor Type
10.2.6.6.3 Rest of Europe Patient Derived Xenograft Models Professional Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Patient Derived Xenograft Models Professional Market Overview
10.3.2 Asia-Pacific Patient Derived Xenograft Models Professional Market Forecasts and Analysis
10.3.3 Asia-Pacific Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Tumor Type
10.3.5 Asia-Pacific Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Patient Derived Xenograft Models Professional Market
10.3.6.1.1 Australia Patient Derived Xenograft Models Professional Market by Type
10.3.6.1.2 Australia Patient Derived Xenograft Models Professional Market by Tumor Type
10.3.6.1.3 Australia Patient Derived Xenograft Models Professional Market by End User
10.3.6.2 China Patient Derived Xenograft Models Professional Market
10.3.6.2.1 China Patient Derived Xenograft Models Professional Market by Type
10.3.6.2.2 China Patient Derived Xenograft Models Professional Market by Tumor Type
10.3.6.2.3 China Patient Derived Xenograft Models Professional Market by End User
10.3.6.3 India Patient Derived Xenograft Models Professional Market
10.3.6.3.1 India Patient Derived Xenograft Models Professional Market by Type
10.3.6.3.2 India Patient Derived Xenograft Models Professional Market by Tumor Type
10.3.6.3.3 India Patient Derived Xenograft Models Professional Market by End User
10.3.6.4 Japan Patient Derived Xenograft Models Professional Market
10.3.6.4.1 Japan Patient Derived Xenograft Models Professional Market by Type
10.3.6.4.2 Japan Patient Derived Xenograft Models Professional Market by Tumor Type
10.3.6.4.3 Japan Patient Derived Xenograft Models Professional Market by End User
10.3.6.5 South Korea Patient Derived Xenograft Models Professional Market
10.3.6.5.1 South Korea Patient Derived Xenograft Models Professional Market by Type
10.3.6.5.2 South Korea Patient Derived Xenograft Models Professional Market by Tumor Type
10.3.6.5.3 South Korea Patient Derived Xenograft Models Professional Market by End User
10.3.6.6 Rest of Asia-Pacific Patient Derived Xenograft Models Professional Market
10.3.6.6.1 Rest of Asia-Pacific Patient Derived Xenograft Models Professional Market by Type
10.3.6.6.2 Rest of Asia-Pacific Patient Derived Xenograft Models Professional Market by Tumor Type
10.3.6.6.3 Rest of Asia-Pacific Patient Derived Xenograft Models Professional Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Patient Derived Xenograft Models Professional Market Overview
10.4.2 Middle East and Africa Patient Derived Xenograft Models Professional Market Forecasts and Analysis
10.4.3 Middle East and Africa Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Tumor Type
10.4.5 Middle East and Africa Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Patient Derived Xenograft Models Professional Market
10.4.6.1.1 South Africa Patient Derived Xenograft Models Professional Market by Type
10.4.6.1.2 South Africa Patient Derived Xenograft Models Professional Market by Tumor Type
10.4.6.1.3 South Africa Patient Derived Xenograft Models Professional Market by End User
10.4.6.2 Saudi Arabia Patient Derived Xenograft Models Professional Market
10.4.6.2.1 Saudi Arabia Patient Derived Xenograft Models Professional Market by Type
10.4.6.2.2 Saudi Arabia Patient Derived Xenograft Models Professional Market by Tumor Type
10.4.6.2.3 Saudi Arabia Patient Derived Xenograft Models Professional Market by End User
10.4.6.3 U.A.E Patient Derived Xenograft Models Professional Market
10.4.6.3.1 U.A.E Patient Derived Xenograft Models Professional Market by Type
10.4.6.3.2 U.A.E Patient Derived Xenograft Models Professional Market by Tumor Type
10.4.6.3.3 U.A.E Patient Derived Xenograft Models Professional Market by End User
10.4.6.4 Rest of Middle East and Africa Patient Derived Xenograft Models Professional Market
10.4.6.4.1 Rest of Middle East and Africa Patient Derived Xenograft Models Professional Market by Type
10.4.6.4.2 Rest of Middle East and Africa Patient Derived Xenograft Models Professional Market by Tumor Type
10.4.6.4.3 Rest of Middle East and Africa Patient Derived Xenograft Models Professional Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Patient Derived Xenograft Models Professional Market Overview
10.5.2 South and Central America Patient Derived Xenograft Models Professional Market Forecasts and Analysis
10.5.3 South and Central America Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Type
10.5.4 South and Central America Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Tumor Type
10.5.5 South and Central America Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By End User
10.5.6 South and Central America Patient Derived Xenograft Models Professional Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Patient Derived Xenograft Models Professional Market
10.5.6.1.1 Brazil Patient Derived Xenograft Models Professional Market by Type
10.5.6.1.2 Brazil Patient Derived Xenograft Models Professional Market by Tumor Type
10.5.6.1.3 Brazil Patient Derived Xenograft Models Professional Market by End User
10.5.6.2 Argentina Patient Derived Xenograft Models Professional Market
10.5.6.2.1 Argentina Patient Derived Xenograft Models Professional Market by Type
10.5.6.2.2 Argentina Patient Derived Xenograft Models Professional Market by Tumor Type
10.5.6.2.3 Argentina Patient Derived Xenograft Models Professional Market by End User
10.5.6.3 Rest of South and Central America Patient Derived Xenograft Models Professional Market
10.5.6.3.1 Rest of South and Central America Patient Derived Xenograft Models Professional Market by Type
10.5.6.3.2 Rest of South and Central America Patient Derived Xenograft Models Professional Market by Tumor Type
10.5.6.3.3 Rest of South and Central America Patient Derived Xenograft Models Professional Market by End User
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. PATIENT DERIVED XENOGRAFT MODELS PROFESSIONAL MARKET, KEY COMPANY PROFILES
13.1. CHAMPIONS ONCOLOGY, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CHARLES RIVER LABORATORIES, INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. CROWN BIOSCIENCE, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. EPO BERLIN-BUCH GMBH
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. HERA BIOLABS
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. HORIZON DISCOVERY GROUP PLC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. ONCODESIGN
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PHARMATEST SERVICES LTD
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. UROLEAD
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. XENTECH
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Champions Oncology, Inc.
2. Charles River Laboratories, Inc.
3. Crown Bioscience, Inc.
4. EPO Berlin-Buch GmbH
5. Hera BioLabs
6. Horizon Discovery Group plc
7. Oncodesign
8. Pharmatest Services Ltd
9. Urolead
10. Xentech
TIPRE00021843
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking